2+ hour, 21+ min ago  (215+ words) In a paper published in Sleep, Yulia Savva and colleagues outline the development of the Functional Impacts of Narcolepsy Instrument (FINI), a novel tool for measuring narcolepsy's functional impact across the domains most relevant to patients. Separate versions of the…...

51+ min ago  (152+ words) The phase 3 NATALEE clinical trial previously demonstrated that adjuvant (adj) ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) significantly improved invasive disease'free survival (i DFS) compared with NSAI alone in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor…...

2+ hour, 44+ min ago  (170+ words) Docwire News OPTIMA Trial in Premenopausal Patients: Practice Implications Abirami Sivapiragasam, MD, discusses how to interpret OPTIMA trial findings in premenopausal patients with ER-positive, HER2-negative early breast cancer, a group where chemotherapy decisions remain challenging. She reviews prior data suggesting…...

1+ hour, 36+ min ago  (274+ words) In the current analysis, the investigators evaluated additional efficacy endpoints designed to assess the durability of treatment benefit beyond first disease progression. Eligible patients with previously untreated locally recurrent inoperable or metastatic TNBC who were not candidates for immunotherapy were…...

4+ hour, 8+ min ago  (236+ words) How practice-changing are the OPTIMA findings for using Prosigna (PAM50) to safely omit chemotherapy in high clinical-risk, node-positive ER+ HER2- early breast cancer? Dr. Sivapiragasam: The OPTIMA trial is one of the most important trial that we are looking forward to hearing…...

1+ day, 22+ min ago  (379+ words) Adjuvant capecitabine plus trastuzumab was associated with excellent long-term outcomes and low rates of serious toxicity among patients with stage IA HER2-positive breast cancer, according to findings from the phase 2 IRIS-A trial presented at the 2026 American Society of Clinical Oncology…...

1+ day, 5+ hour ago  (210+ words) Anbenitamab (KN026) is a biparatopic HER2 antibody that targets two distinct HER2 domains (II and IV). This open-label phase 3 trial aimed to classify whether an anbenitamab-based regimen could improve outcomes in patients with HER2-positive early or locally advanced breast cancer, where achieving a pathologic…...

1+ day, 22+ hour ago  (333+ words) Giredestrant demonstrates invasive disease-free survival (IDFS) benefit regardless of menopausal status among patients with estrogen receptor-positive/HER2-negative (ER+/HER2-) early breast cancer (e BC), according to findings from the phase 3 lid ERA BC trial to be presented at the 2026 American Society…...

2+ day, 1+ hour ago  (373+ words) An in-depth safety analysis from the phase 3 HER2 CLIMB-05 trial suggests that adding tucatinib to trastuzumab and pertuzumab maintenance therapy has a clinically manageable safety profile among patients with HER2-positive metastatic breast cancer (MBC), according to findings to be presented at…...

2+ day, 2+ hour ago  (309+ words) This exploratory analysis evaluated efficacy and safety outcomes according to patients" best confirmed response to trastuzumab deruxtecan plus pertuzumab (T-DXd + P) from the DESTINY-Breast09 trial. In the phase 3 DESTINY-Breast09 trial, researchers randomized patients in a 1: 1: 1 ratio to receive T-DXd + P (trastuzumab…...